This company listing is no longer active
Aptinyx (APTX) Stock Overview
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
APTX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Aptinyx Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.096 |
| 52 Week High | US$0.72 |
| 52 Week Low | US$0.009 |
| Beta | 1.22 |
| 1 Month Change | 46.12% |
| 3 Month Change | 43.07% |
| 1 Year Change | -73.43% |
| 3 Year Change | -97.32% |
| 5 Year Change | -99.48% |
| Change since IPO | -99.52% |
Recent News & Updates
Recent updates
Aptinyx musculoskeletal pain drug NYX-2925 fails mid-stage study
Aug 12We're Keeping An Eye On Aptinyx's (NASDAQ:APTX) Cash Burn Rate
Aug 18
Aptinyx: CNS Drug Discoverer With Depressed Price
Jul 21Aptinyx (NASDAQ:APTX) Is In A Good Position To Deliver On Growth Plans
Apr 13Did You Miss Aptinyx's (NASDAQ:APTX) 15% Share Price Gain?
Mar 09What Kind Of Shareholders Hold The Majority In Aptinyx Inc.'s (NASDAQ:APTX) Shares?
Jan 30
Have Insiders Been Buying Aptinyx Inc. (NASDAQ:APTX) Shares This Year?
Dec 26What Type Of Returns Would Aptinyx's(NASDAQ:APTX) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Nov 27Shareholder Returns
| APTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 10.9% | 3.1% | 4.0% |
| 1Y | -73.4% | 44.7% | 38.7% |
Return vs Industry: APTX underperformed the US Biotechs industry which returned 7.1% over the past year.
Return vs Market: APTX underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| APTX volatility | |
|---|---|
| APTX Average Weekly Movement | 19.1% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: APTX's share price has been volatile over the past 3 months.
Volatility Over Time: APTX's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 12 | Craig Jalbert | www.aptinyx.com |
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc.
Aptinyx Inc. Fundamentals Summary
| APTX fundamental statistics | |
|---|---|
| Market cap | US$6.50m |
| Earnings (TTM) | -US$66.09m |
| Revenue (TTM) | n/a |
Is APTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$35.74m |
| Gross Profit | -US$35.74m |
| Other Expenses | US$30.35m |
| Earnings | -US$66.09m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.98 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 137.5% |
How did APTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/01/03 23:16 |
| End of Day Share Price | 2023/12/29 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aptinyx Inc. is covered by 11 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gary Nachman | BMO Capital Markets Equity Research |
| Charles Duncan | Cantor Fitzgerald & Co. |
| Raghuram Selvaraju | H.C. Wainwright & Co. |